Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX)
CUSIP: 501976104
Q1 2024 13F Holders as of 31 Mar 2024
- Type / Class
- Equity / Common Stock, par value $0.00001 per share
- Shares outstanding
- 56,833,213
- Total 13F shares
- 30,688,965
- Share change
- +30,628,165
- Total reported value
- $762,283,849
- Put/Call ratio
- 10350%
- Price per share
- $24.84
- Number of holders
- 88
- Value change
- +$760,773,578
- Number of buys
- 87
Quarterly Holders Quick Answers
What is CUSIP 501976104?
CUSIP 501976104 identifies KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Newer quarter: Q2 2024
Recent filing periods for CUSIP 501976104:
Top shareholders of KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Vida Ventures, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,777,060
|
— | — | 12 Feb 2024 | |
| GILEAD SCIENCES, INC. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,126,119
|
— | — | 12 Feb 2024 | |
| Northpond Ventures III GP, LLC |
3/4/5
|
Former 10% Owner |
—
class O/S missing
|
3,255,426
|
— | — | 12 Feb 2024 | |
| Bain Capital Life Sciences Investors, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,163,868
|
— | — | 12 Feb 2024 | |
| Westlake BioPartners Fund I, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
735,984
|
— | — | 12 Feb 2024 | |
| Dominique Christian Borie |
3/4/5
|
President, Research and Development Exhibit 24 - Power of Attorney |
—
class O/S missing
|
449,210
|
— | — | 07 Feb 2024 | |
| Peter Maag |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
407,541
|
— | — | 07 Feb 2024 | |
| James Bum Chung |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
65,918
|
— | — | 07 Feb 2024 |
Institutional Holders of Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX) as of Q1 2024
As of 31 Mar 2024,
Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX) was held by
88 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
30,688,965 shares.
The largest 10 holders included
Vida Ventures Advisors, LLC, Northpond Ventures, LLC, Bain Capital Life Sciences Investors, LLC, RTW INVESTMENTS, LP, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), JENNISON ASSOCIATES LLC, PRICE T ROWE ASSOCIATES INC /MD/, Insight Holdings Group, LLC, COMMODORE CAPITAL LP, and JPMORGAN CHASE & CO.
This page lists
88
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2024 vs Q4 2025 Across Filers
Q4 2025 holders
99
Q1 2024 holders
88
Holder diff
-11
| Investor | Q4 2025 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.